Citius Pharmaceuticals (CTXR) Operating Income (2010 - 2026)

Citius Pharmaceuticals (CTXR) has reported Operating Income for 17 consecutive years, with -$11.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income fell 33.5% year-over-year to -$11.7 million; the trailing twelve-month figure through Jun 2026 stood at -$61.4 million (down 49.21% YoY), and the FY2025 full-year result was -$38.5 million, up 8.26% from the prior year.
• Operating Income rose to -$11.7 million in Q2 2026 per CTXR's latest filing, from -$32.2 million in the prior quarter.
• Across five years, Operating Income topped out at -$7.2 million in Q4 2022 and bottomed at -$32.2 million in Q1 2026.
• Historically, Operating Income has averaged -$10.8 million across 5 years, with a median of -$9.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Income grew 23.65% in 2025, then tumbled 185.9% in 2026.
• Over 5 years, Operating Income stood at -$7.2 million in 2022, then decreased by 28.84% to -$9.3 million in 2023, then dropped by 7.48% to -$10.0 million in 2024, then increased by 10.16% to -$9.0 million in 2025, then tumbled by 30.08% to -$11.7 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$11.7 million, -$32.2 million, and -$9.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.